Vandetanib has 23 known drug interactions based on U.S. FDA drug labeling data. 18 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Alogliptin And Metformin Hydrochloride, Dapagliflozin And Metformin Hydrochloride, Empagliflozin And Metformin Hydrochloride. Patients taking Vandetanib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 23
- Major
- 18
- Moderate
- 4
Major (18)
- Vandetanib + Alogliptin And Metformin Hydrochloride— May increase metformin accumulation and risk of lactic acidosis by reducing metformin clearance through OCT2/MATE inhibi…
- Vandetanib + Dapagliflozin And Metformin Hydrochloride— OCT2/MATE inhibitor that increases metformin exposure and may increase risk for lactic acidosis.
- Vandetanib + Empagliflozin And Metformin Hydrochloride— Vandetanib inhibits metformin clearance via OCT2/MATE, increasing metformin exposure and risk of lactic acidosis.
- Vandetanib + Empagliflozin, Linagliptin, Metformin Hydrochloride— OCT2/MATE inhibitor that interferes with renal elimination of metformin, increasing systemic exposure and risk of lactic…
- Vandetanib + Empagliflozin, Metformin Hydrochloride— OCT2/MATE inhibitor that may increase systemic metformin exposure and increase risk for lactic acidosis.
- Vandetanib + Ertugliflozin And Metformin Hydrochloride— Increases risk of lactic acidosis by reducing metformin clearance through OCT2/MATE inhibition.
- Vandetanib + Glyburide And Metformin Hydrochloride— OCT2/MATE inhibitor that reduces metformin clearance and may increase risk for lactic acidosis.
- Vandetanib + Linagliptin And Metformin Hydrochloride— OCT2/MATE inhibitor that reduces metformin clearance, increasing systemic exposure and risk of lactic acidosis.
- Vandetanib + Metformin— Reduces metformin clearance by inhibiting renal tubular transport, increasing systemic exposure and lactic acidosis risk…
- Vandetanib + Metformin Er 500 Mg— OCT2/MATE inhibitor that reduces metformin clearance, increasing systemic exposure and risk of lactic acidosis.
- Vandetanib + Metformin Hydrochloride— OCT2/MATE inhibitor that reduces metformin clearance and may increase risk of lactic acidosis through increased systemic…
- Vandetanib + Metformin Hydrochloride Extended-Release Tablets— OCT2/MATE inhibitor that reduces metformin clearance, increasing systemic exposure and risk for lactic acidosis.
- Vandetanib + Metformin Hydrochloride Tablet— Reduces metformin clearance via OCT2/MATE inhibition, increasing systemic exposure and risk of lactic acidosis.
- Vandetanib + Pioglitazole And Metformin Hydrochloride— OCT2/MATE inhibitor reduces metformin clearance, increasing systemic exposure and risk for lactic acidosis. Consider ben…
- Vandetanib + Rifampin— Strong CYP3A4 inducer that decreases vandetanib plasma concentrations. Avoid concomitant use during CAPRELSA therapy.
- Vandetanib + Saxagliptin And Metformin Hydrochloride— OCT2/MATE inhibitor that reduces metformin clearance, increasing systemic exposure and risk for lactic acidosis.
- Vandetanib + Sitagliptin And Metformin Hydrochloride— Inhibits metformin renal clearance via OCT2/MATE transporter interference, increasing systemic metformin exposure and la…
- Vandetanib + St. John'S Wort— Can decrease vandetanib exposure unpredictably. Avoid concomitant use during CAPRELSA therapy.
Moderate (4)
- Vandetanib + Canagliflozin And Metformin Hydrochloride— OCT2/MATE inhibitor that reduces metformin clearance and may increase risk for lactic acidosis. Consider benefits and ri…
- Vandetanib + Digoxin— CAPRELSA increases plasma concentrations of digoxin. Use caution and closely monitor for toxicities.
- Vandetanib + Glyburide-Metformin Hydrochloride— OCT2/MATE inhibitor that reduces metformin clearance and may increase risk for lactic acidosis.
- Vandetanib + Itraconazole— Bortezomib Brentuximab vedotin Busulfan a Erlotinib Gefitinib a Idelalisib Imatinib Ixabepilone Nintedanib Panobinostat …